Introduction
the Tat transactivation process. We also found that K-12 is a potent and selective inhibitor of the replication of several herpesviruses.
Materials and Methods

Compounds
The fluoroquinolone derivative ( Fig. 1 ) 8-difluoromethoxy-1-ethyl-6-fluoro-1,4-dihydro-7-[4-(2methoxyphenyl)-1-piperazinyl]-4-quinolone-3-carboxylic acid (K-12) was synthesized by Daiichi Pharmaceutical Company (Tokyo, Japan) and saquinavir (Ro31-8959) {QC.AsnPhe[CH(OH)CH 2 N]DIQ.NHtBu, where QC is quinoline-2-carbonyl, DIQ is (4as,8as)-decahydro-3(S)isoquinolinecarbonyl and tBu is tert-butyl} was provided by N Roberts (Roche Products, Welwyn Garden City, UK). AZT was obtained from Sigma and ritonavir (ABT538) was kindly provided by JM Leonard (Pharmaceutical Products Division, Abbott Laboratories, North Carolina, Ill., USA). Stock solutions (20 mg/ml) were prepared in DMSO, divided into aliquots and stored at -20°C under light-protected conditions. Nevirapine (BI-RG-587) was provided by Boehringer Ingelheim Pharmaceuticals.
Cells MT-4 (Miyoshi et al., 1982) , C8166 (Salahuddin et al., 1983) , CEM (Foley et al., 1965) and HUT-78 (Gazdar et al., 1980) cells were grown and maintained in RPMI 1640 medium; E 6 SM, Vero, HEL, OMK (Owl monkey kidney; ATCC CRL-1556) and HeLa cells were maintained in Eagle's MEM. Both media were supplemented with 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 0.1% sodium bicarbonate and 20 µg/ml gentamicin. Peripheral blood mononuclear cells (PBMCs) were isolated from HIV-seronegative donor buffy coats using a Ficoll gradient (Lymphoprep; Nycomed), stimulated for 3 days in medium containing phytohaemagglutinin (PHA-P; 2 µg/ml; Sigma), washed and resuspended in RPMI 1640 supplemented with 2 mM L-glutamine, gentamicin (50 µg/ml), 15% heat-inactivated fetal calf serum, and recombinant human interleukin 2 (10 U/ml; Boehringer Mannheim). Chronically HIV-1 IIIB -infected HUT-78 cells were obtained after infection of HUT-78 cells with HIV-1 strain IIIB (Popovic et al., 1984) .
Viruses
The origins of the following virus stocks have been described previously: herpes simplex virus type 1 (HSV-1) KOS strain, HSV-2 G strain, thymidine kinase-negative (TK -) HSV-1 strain B2006 (De Clercq et al., 1980) , TK -HSV-1 strain VMW-1837 (Vinckier et al., 1987) , human herpesvirus type 8 (HHV-8) (Neyts & De Clercq, 1997) , varicella-zoster virus (VZV) (Snoeck et al., 1998) , Moloney murine sarcoma virus (MSV) (De Clercq & Merigan, 1971) , vaccinia virus (VV), vesicular stomatitis virus (VSV), Coxsackie virus type B4 (CBV), Sindbis virus (De Clercq et al., 1975) , respiratory syncytial virus (RSV) Long strain (Kawana et al., 1987) , HIV-1 IIIB and RF (Popovic et al., 1984) and HIV-1 NDK (Spire et al., 1989) . HIV-1 ADP/141, a recombinant AZT-resistant HIV-1 strain [reverse transcriptase (RT) mutations: D67N, K70R, T215F and K219Q] was obtained through the Medical Research Council's AIDS Reagent Project (National Institute for Biological Standards and Control, UK) and were contributed by B Larder and S Kemp (Larder & Kemp, 1989) . HIV-2 ROD (Barré-Sinoussi et al., 1983) and HIV-2 EHO were obtained from the culture supernatants of HIV-1-or HIV-2-infected cell lines (Pauwels et al., 1987; Schols et al., 1989a) . Simian immunodeficiency (SIV) strain MAC251 was originally isolated by Daniel et al. (1987) and was obtained from C Bruck (Smith Kline-RIT, Rixensart, Belgium); SIV stocks were prepared from the supernatants of SIV-infected MT-4 cells. Reovirus type 1 (ATCC VR-230), herpesvirus saimiri (HVS) (strain S295C; ATCC 608), human cytomegalovirus (HCMV) [Davis strain (ATCC VR-807) and AD-169 strain (ATCC VR-538)], parainfluenza virus type 3 (PIV-3; ATCC VR-93) and Punta Toro virus (ATCC VR-559) were obtained from the ATCC. HIV-1 strain B12 was isolated from an HIV-1-infected patient after 1 year of ritonavir monotherapy (courtesy of B Clotet and L Ruiz, Barcelona, Spain). HIV-1 B12 stocks were prepared from the supernatants of PBMCs infected with the patient's plasma (Schmit et al., 1996) .
Antiviral activity assays
For HSV, VV, HCMV, VZV, VSV, CBV, PIV-3, Sindbis virus, Punta Toro virus and reovirus type 1, the assay procedures have been described previously (De Clercq et al., 1975 De Clercq & Merigan, 1971 ; Andrei & De . A similar procedure in OMK cells was used for HVS. Confluent (E 6 SM, Vero, HeLa, HEL or OMK) cell cultures in 96-well microtitre trays were exposed to 100 CCID 50 virus/well (with 1 CCID 50 being the 50% cell culture infective dose) in the presence of various concentrations of the test compounds diluted in Eagle's MEM supplemented with 3% fetal calf serum, 2 mM L-glutamine and 0.1% sodium bicarbonate. For RSV, confluent cell cultures (HeLa cells) in microtitre trays were inoculated with 20 CCID 50 virus/well. The cells were further incubated in the presence of various concentrations of the test compounds and were monitored for virus-induced cytopathicity as described previously (Kawana et al., 1987) . The cells were further incubated at 37°C until virus-induced cytopathicity was completed in the control (virus-infected, untreated) cell cultures.
The inhibitory effects of K-12 on HIV-1, HIV-2 and SIV replication were monitored by the inhibition of virusinduced cytopathicity in MT-4, C8166 and CEM cells as described previously (Pauwels et al., 1988; Balzarini et al., 1993) . Cytotoxicity of the compounds was determined by measuring the viability of mock-infected cells at day 4 for CEM cells and day 5 for MT-4 and C8166 cells. The inhibitory effect of K-12 on HHV-8 replication was monitored by the reduction of HHV-8 DNA synthesis in TPAstimulated BCBL-1 cells, as described previously (Neyts & De Clercq, 1997) . Virus-induced cytopathic effect was recorded at 1 or 2 days post-infection (p.i.) for VSV; at 2 days p.i. for CBV; at 2 or 3 days p.i. for HSV-1 KOS, HSV-2 G, HSV-1 TK -B2006, HSV-1 TK -VMW-1837, VV and Sindbis virus; at 3 days p.i. for RSV; at 4 or 5 days p.i. for PIV-3 virus; at 5 days p.i. for HIV and SIV; and at 6-7 days p.i. for reovirus, MSV, HCMV, HVS and HHV-8. For the anti-MSV assays, murine C3H/3TC embryo fibroblast cells were infected with 80 focus-forming units (f.f.u.) of MSV, and transformation of the cell cultures was scored microscopically at day 6 after infection, as described previously (Balzarini et al., 1989) . PBMCs were plated in the presence of different concentrations of the test compound and were infected with HIV-1 IIIB at 1000 CCID 50 /ml. At 4 days p.i., half of the supernatant of the infected cultures was removed and replaced with fresh medium containing the test compound at the appropriate concentration. At 7 days after plating, p24 antigen was detected in the culture supernatant by ELISA (Du Pont).
Inhibitory effects on chronically HIV-infected cells
Chronically HIV-1 IIIB -infected HUT-78 cells were washed twice (to remove cell-free virus) and resuspended at 100000 cells/ml in fresh medium containing the test compound at the appropriate concentration. After 72 h of incubation at 37°C the supernatants of the cell cultures were collected to determine virus titres in MT-4 cells by the endpoint dilution method of Reed & Muench (1938) .
Syncytium formation
MOLT-4 (clone 8) cells (1.8×10 6 cells/ml) were cultured with persistently HIV-1-or HIV-2-infected HUT-78 cells (2×10 5 cells/ml) in microtitre tray wells containing various concentration of the test compounds. After a 24 h cocultivation period, the number of giant cells (syncytia) was recorded microscopically, as described previously (Baba et al., 1990) .
RT assay
Poly(rC) . oligo(dG) was used as the template-primer and [ 3 H]dGTP as radiolabelled substrate. The final [ 3 H]dGTP concentration in the reaction mixture was 2.5 µM.
In vitro cleavage and integration assay
This assay was performed as described previously (Cherepanov et al., 1997) . Briefly, the 20 bp 32 P-labelled substrate for in vitro assays that mimics the U5 end of HIV-1 DNA was prepared (Sherman & Fyfe, 1990 ). The 10 µl reaction mixtures for cleavage-integration assays contained 20 mM HEPES pH 7.5, 5 mM DTT, 10 mM MgCl 2 , 5% polyethylene glycol 8000, 15% DMSO and 0.2 pmol of the oligonucleotide substrate. The reactions were started by the addition of 100 ng integrase. The final NaCl concentration was 75 mM. The reactions were performed at 35°C for 40 min and stopped by adding an equal volume of the gel loading buffer (95% formamide, 30 mM EDTA, 0.1% xylene cyanol, 0.1% bromophenol blue). Quantification of the results was performed with the PhosphoImager system (Molecular Dynamics). The products were separated on a 17% denaturing polyacrylamide gel. Autoradiography was performed by exposing the wet gel to X-ray film (CURIX RP1; Agfa).
Inhibitory effects of K-12 and nevirapine on the appearance of HIV-1 IIIB proviral DNA in MT-4 cells MT-4 cells were infected with HIV-1 IIIB at a high m.o.i. (0.1 to 1). The test compounds were added together with the virus, and the cells were harvested 24 h after infection. The cells were washed twice with PBS and were suspended in Milli-Q water (Millipore). An aliquot of 10000 cells was then transferred to a 0.5 ml Eppendorf tube, overlaid with 20 µl of mineral oil and lysed at 94°C for 20 min. PCR was performed on a PE-9600 instrument in a total volume of 50 µl with 10 mM Tris-HCl pH 8.3, 50 mM KCl, 1.5 mM MgCl 2 , 200 µM of each deoxynucleoside triphosphate, 1 µM of each primer and 1.25 U of AmpliTaq DNA polymerase (Perkin-Elmer Cetus). Two primer pairs (synthesized by A Van Aerschot, Leuven, Belgium) were used: the repliprimers to amplify a 263 bp fragment in the pol region of HIV-1 and two globin primers (primers PC03 and KM38) to amplify a 167 bp fragment of the human β-globulin gene (Vandamme et al., 1995) . Eight µl of each sample was electrophoresed in a 4%
Nusieve-Seakem (3:1) blend (FMC Bioproducts) and the DNA was stained with ethidium bromide.
Inhibition of HIV-1 transactivation
Tat-dependent transactivation was monitored mainly as described previously (Daelemans et al., 1997) with the following modifications. HLtat (HeLa cells expressing HIV-1 transactivator; kindly provided by G Pavlikis; Felber et al., 1990) were transfected with pHIVLacZ [kindly provided by JJ Maio; Maio & Brown, 1988) or pCMV-β (McGregor & Caskey, 1989) plasmid DNA by electroporation with an Eurogentec Genepulser (260 V, 1050 µF and infinite R). pHIVLacZ contains a LacZ gene driven by the HIV-1 long terminal repeat (LTR) promoter, and pCMV-β expresses the LacZ gene under control of the HCMV promoter. Ro5-3335, previously reported as an HIV-1 LTR transactivation inhibitor (Hsu et al., 1991; Witvrouw et al., 1992) , was used as the reference compound.
The electroporated cells (6×10 4 /well) were incubated in microtitre plates for 24 h in the presence of varying concentrations of the test compounds. Then, the medium was removed by gentle aspiration and the monolayers were washed with PBS. Cells were lysed with 25 µl of 0.5% Nonidet P-40, and β-galatosidase (β-gal) activity in 20 µl of the cell extracts was quantified by a colorimetric assay as described by Sambrook et al. (1989) . Then, 5 µl of cell extract was used to determine total protein content according to the Bradford method (BioRad). The IC 50 value was calculated as the inhibitor concentration that reduced β-gal expression by 50%.
Time-of-addition experiments
MT-4 cells were infected with HIV-1 IIIB at a m.o.i. of 1 and the compounds were added at different times (hourly, from 0 to 26 h) after infection. Viral p24 antigen production was determined 31 h p.i. The reference compounds were added at a standardized concentration of 100× EC 50 [concentration required to reduce the cytopathicity of HIV-1 IIIB (m.o.i. 0.01) in MT-4 cells by 50%; De .
Virucidal effect of K-12
The virucidal effect of K-12 was tested by treatment of an undiluted stock of HIV-1 IIIB with various concentrations of K-12. After 1 h of incubation at room temperature, the virus titres were determined in MT-4 cells by the endpoint dilution method of Reed & Muench (1938) .
Results
Antiretroviral activity spectrum K-12 ( Fig. 1 ) was found to inhibit HIV-1 IIIB replication at 0.2 µM in MT-4 and C8166 cells (Table 1) , while it was cytotoxic at approximately 2.5 µM, resulting in a selectivity index of 12.5. Higher selectivities were seen in CEM cells and PBMCs, where K-12 showed an EC 50 of 0.2 and 0.6 µM, respectively, with CC 50 values of 24 µM. The anti-HIV activity of K-12 was confirmed for various strains of HIV-1 (subtype B: IIIB, RF; subtype D: NDK), HIV strains resistant to nucleoside RT inhibitors (NRTIs) and an HIV protease inhibitor-resistant clinical isolate (B12), various HIV-2 strains (ROD and EHO) and SIV (MAC251) (Table 1) at EC 50 values ranging from 0.2 to 0.5 µM in vitro. K-12 was inhibitory to MSV-induced transformation of murine C3H/3T3 cells at an EC 50 of 6.9 µM (Table 1) , but it proved toxic to the cell monolayer at threefold higher concentrations.
Antiviral activity of K-12 against viruses other than retroviruses
When K-12 was examined for its inhibitory effect on the replication of DNA viruses, it proved inhibitory to HVS, HCMV, VZV and HSV-1 and -2 (in order of decreasing sensitivity), but not inhibitory to HHV-8 (in BCBL-1 cells) (Table 1) . K-12 was found to be inactive against the following RNA viruses: Sindbis virus, VSV, RSV, CBV, Punta Toro virus, PIV-3 and reovirus type 1.
Inhibition of chronic HIV-1 infection
When K-12 was evaluated for its inhibitory effect on virus production by chronically HIV-1 IIIB -infected HUT-78 cells, we noted a concentration-dependent inhibition of the release of infectious virus within the concentration range 0.02-4 µM. At a subtoxic concentration of 4 µM, K-12 reduced the HIV-1 progeny yield by 2.5 log 10 . At 0.8 µM, K-12 still inhibited the release of infectious virus by more than 1 log 10 (Fig. 2) . At concentrations higher or equal to 10 µM, K-12 proved to be toxic for HIV-1 IIIB -infected HUT-78 cells. Saquinavir abolished the HIV-1 infectivity completely at 4 µM. No microscopically detectable cytotoxicity was observed at this concentration.
Syncytium formation
K-12 failed to inhibit HIV-induced syncytium formation upon cocultivation of persistently HIV-1-and HIV-2infected HUT-78 cells with uninfected MOLT-4 cells (data not shown) under conditions where dextran sulphate, a sulphated polysaccharide, effectively suppressed these events (Schols et al., 1989a,b; Witrouw et al., 1991) .
RT assay
K-12, at 205 µM, failed to inhibit HIV-1 RT when poly(rC) . oligo(dG) was used as the template-primer and [ 3 H]dGTP was used as the substrate under conditions where TIBO R86183 (Pauwels et al., 1994) at a concentration of 0.08 µg/ml (0.25 µM) inhibited RT activity by 50% (data not shown).
Integrase catalytic assay
This assay monitors the two consecutive reactions executed by HIV integrase: the cleavage of the viral LTR and the insertion of the LTR into a foreign DNA molecule. The compound K-12 showed no inhibitory effect on the LTR cleavage reaction in the concentration range 0.3-205 µM.
PCR analysis
PCR analysis (Fig. 3) revealed that K-12 at 10.2 µM did 
Inhibition of HIV-1 transactivation
The β-gal transactivation assay allows the quantification of HIV-1 LTR transactivation by Tat in HLtat cells after transient transfection with pHIVLacZ. After Tat-dependent transactivation of the HIV-1 LTR, the expression of β-gal activity was increased up to 50-fold; therefore, these assays provide a sensitive way to study HIV-1 LTR activity. The compound Ro5-3335, previously reported to be an inhibitor of transactivation, inhibited the Tat-dependent expression of the LacZ gene at an IC 50 of 0.44 µM, a result that is in agreement with previous reports (Hsu et al., 1991; Witvrouw et al., 1992) . We found that K-12 was also able to inhibit Tat-dependent β-gal expression (IC 50 7.1 µM) (Fig. 4) . K-12 was not able to inhibit β-gal expression in cells transiently transfected with pCMV-β DNA, a plasmid containing the Tat-independent HCMV immediate early promoter driving the LacZ gene.
Time (site) of intervention
Time-of-addition experiments (Fig. 5a,b) , in which the test compounds were added at different times after infection, indicated that K-12 interacts with a late step of the virus replicative cycle at more than 15 h p.i., prior to the protease activity step. Indeed, when the addition of K-12 was delayed until 15 h p.i., it still elicited marked activity. Dextran sulphate was found to interact at an immediate early step (virus adsorption) and AZT at an early step (reverse transcription), respectively (Fig. 5a ), whereas the protease inhibitors ritonavir and saquinavir (Fig. 5b) interact with a late stage of the virus replicative cycle.
Virucidal activity
K-12 did not show any virucidal activity at 8.3 µM, whereas chlorohexidine at 0.008% reduced the virus titre by 1.6 log 10 (data not shown).
Discussion
We have shown that the fluoroquinolone derivative K-12 is active against both acute HIV-1 and HIV-2 infection (Table 1) . K-12 is active against laboratory strains and clinical isolates of HIV in CD4 + lymphocyte lines (such as MT-4, C8166 and CEM cells) and PBMCs. The compound has similar activity against NRTI-and protease inhibitor-resistant HIV-1 strains in MT-4 and C8166 cells, respectively (Table 1) . Also, K-12 inhibited SIV (MAC251) replication and MSV-induced transformation of murine C3H/3T3 cells. In addition to the retroviruses, K-12 was found to inhibit HVS, HCMV, VZV and HSV-1 and -2 ( Table 1) .
The recent progress in combination treatment regimens has achieved considerable and long-lasting reduction of levels of viral plasma RNA in AIDS patients, but therapy cannot be terminated unless long-lived chronically HIVinfected cell populations are completely eradicated (Perelson et al., 1996) . Since eradication is difficult to achieve, effective compounds should have potent and selective activity in chronically infected cells. Here we have shown that K-12 has such activity in persistently HIV-1 IIIB -infected HUT-78 cells.
K-12 exhibits a mode of anti-HIV action that is clearly different from the modes of action of any of the other anti-HIV agents that are presently used in the treatment of HIV infection. K-12 is not inhibitory to (i) HIV-induced syncytium formation; (ii) HIV RT; or (iii) HIV integrase. Time-of-addition experiments revealed that K-12 interacts at a late stage of virus replication (Fig. 5a,b) , prior to the protease activity step at more than 15 h after infection. This conclusion was confirmed by the finding that K-12 is active against chronic HIV infection in HUT-78 cells (Fig.  2) and does not affect the appearance of HIV-1 IIIB proviral DNA (Fig. 3) . Baba et al. (1997) have suggested that piperazinylquinolone derivatives are inhibitors of HIV-1 transcription and that the target is a cellular factor (or factors) necessary for the transcription of viral DNA.
In this study, we showed K-12 to be active in a transient β-gal transactivation assay for Tat-mediated transactivation (Fig. 4 ). If the target of K-12 is a vital cellular factor, K-12 acts either by influencing the expression of that factor or by interfering with its function in HIV-1 LTR transactivation. Several Tat-binding proteins have been described (Nelbock et al., 1990; Shibuya et al., 1992) . The loop sequences of TAR RNA serve as binding sites for other cellular factors ( Gatignol et al., 1989 Gatignol et al., , 1991 Gaynor et al., 1989; Wu et al., 1991) . The mechanism of the molecular interaction of K-12 with Tat-mediated transactivation still has to be elucidated. This may lead to a better understanding of the process of transactivation and, eventually, to the development of better transactivation inhibitors. K-12 did not inhibit the reporter gene expression driven by the Tat-independent HCMV immediate early promoter (Fig. 4) , although it is active against HCMV replication. These data are in agreement with our postulated mechanism of action of K-12: interaction with the mechanism of Tat-mediated transactivation. Before we can conclude that K-12 inhibits HCMV replication or the replication of herpesviruses in general by the same mechanism, further experiments with herpesvirus promoter-driven Tat transactivation assays should be performed.
In conclusion, the fluoroquinolone derivative K-12 is an interesting new anti-HIV agent targeted at the Tat transactivation process. The activity spectrum of K-12 extends to herpesviruses, including viruses (such as VZV, HSV and HCMV) that occur as opportunistic pathogens in AIDS patients. MT-4 cells were infected with HIV-1 IIIB at an m.o.i. of >1, and the test compounds were added at different times p.i. Viral p24 antigen production was determined at 31 h p.i. and is expressed as absorbance (OD) units. Symbols: (■), dextran sulphate (molecular weight 5000; 20 µM); (▲), AZT (1.9 µM); (•), K-12 (8.4 µM), (❏), ritonavir (2.8 µM), ( ), saquinavir (0.7 µM).
